NPPA Revises Retail Prices Of 22 Formulations

NPPA Revises Retail Prices Of 22 Formulations

Mumbai, 14 June 2018: The National Pharmaceutical Pricing Authority (NPPA) has revised retail prices of 22 formulations under Drugs (Prices Control) Order, 2013 in a notification dated 12 June 2018. 


Name of the formulations are methylcobalamin + alpha lipoic acid + pyridoxine hydrochloride+folic acid + vitamin D3 1000IU tablet, cefixime + cloxacillin+lactic acid tablet (ZIFI LBX +200), omeprazole + domperidone capsule (OZSON – DSR), clotrimazole+ beclomethasone cream (CZSON- B), clotrimazole+ beclomethasone+ neomycin cream (CZSON- NB), linezolid suspension (ZIFI TURBO KID), suspension (LIZOFLY), rosuvastatin + clopidogrel tablet (ROSUVAS CV 10), olmesartan + amlodipine +  amlodipine tablet (Triolmezest CH 20), olmesartan+ amlodipine + amlodipine tablet (Triolmezest CH 40), telmisartan + amlodipine +  chlorthalidone tablet (Telvas 3D CT 40/6.25),  telmisartan+  amlodipine+ chlorthalidone tablet (Telvas 3D CT 80/6.25), Alpha lipoic + vitamin D3 + pyridoxine + mecobalamin + folic  acid + biotin tablet (Nervijen D3 ) Omega - 3  ( Eicosapentaenoic +  Docosahexaenoic) +  mecobalamine +  pyridoxine +  folic  acid + vitamin E +  vitamin C + zinc  sulphate+sodium selenite capsule (Omegaful), thiamine mononitrate + pyridoxine hydrochloride + cyanocobalamin + nicotinamide + calcium pantothenate + riboflavin + vitamin C + folic acid tablet (Sioneuron F), tenofovir  disoproxil fumarate + lamividine + efavirenz tablet (AVONZA), diclofenac + methyl salcylate + menthol (Volini Maxx Spray in 55gm pack)


The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form - III of Schedule - II of the DPCO, 2013 through IPDMS.


Any manufacturer intending to discontinue production of said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form -IV of Schedule - II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.


The manufacturers not complying with the ceiling price and notes specified shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.


Consequent to the issue of ceiling prices of such formulations as specified, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. Pharmabiz